Rigel Pharma (RIGL) Tops Q3 EPS by 4c
Tweet
Share
E-mailGet Alerts RIGL Hot Sheet
Price: $48.67 +0.35%
EPS Growth %: -34.9%
Financial Fact:
Contract revenues from collaborations: 3.76M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -34.9%
Financial Fact:
Contract revenues from collaborations: 3.76M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Rigel Pharma (NASDAQ: RIGL) reported Q3 EPS of ($0.03), $0.04 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $28.1 million versus the consensus estimate of $27.2 million.
For earnings history and earnings-related data on Rigel Pharma (RIGL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- RBC Capital Reiterates Outperform Rating on Aviva PLC (AV:LN) (AVVIY)
- Lynx Equity sees Micron and SanDisk breakout as volatility normalizes
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
